PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15245362

Atopic keratoconjunctivitis.

S Bonini
View original source ↗Export metadata ↓

Abstract

Atopic keratoconjunctivitis (AKC) represents a disease usually classified under the term of allergic conjunctivitis together with seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC) and vernal keratoconjunctivitis (VKC). However, AKC and VKC have clinical and pathophysiological features quite different from SAC and PAC, in spite of some common markers of allergy. This article aims to review personal studies suggesting that allergic conjunctivitis (similarly to asthma, rhinitis and atopic dermatitis) is a heterogeneous disease entity with different preferential pathogenetic mechanisms and a spectrum of clinical expression which varies according to individual cases. AKC and VKC may thus represent a model of atopy quite distinct from the classical type-1 hypersensitivity mechanism.

Explore related subjects

Conjunctivitis, AllergicEosinophilsHumansImmunoglobulin EImmunologic TestsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Bonini. 2004. Atopic keratoconjunctivitis.. https://doi.org/10.1111/j.1398-9995.2004.00570.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Rhinoconjunctivitis caused by paper tissues].

Rhinoconjunctivitis can be caused by allergenic as well as non-allergenic factors. When no allergy is involved, it is important to ask the patient about possible daily exposure to factors that may irritate the mucous membranes. The work environment may play a part, but other things may also be provoking factors, including paper tissues, which, besides the fibres of the paper itself, may contain chemical substances that irritate the mucous membranes. The treatment is to replace the paper tissues with well-washed cotton handkerchiefs. The use of a nasal steroid may be necessary for a short time.

Conjunctivitis, Allergic↗
PubMed2006

Pharmacology of ocular allergy.

PURPOSE OF REVIEW: To evaluate the pharmacology of current drug development directed towards ocular allergy. Increased worldwide prevalence of ocular allergy has stimulated expansion of management strategies towards physiologic and immunologic drug targets. RECENT FINDINGS: Present drug targets are located in the conjunctival mucosal surface at the initial site of allergen exposure. Pharmacologic intervention attends to early and late phase reactions. Targets generating a response include mast cells, IgE, released preformed mediator histamine, and newly formed mediators, such as prostaglandins, leukotrienes and cytokines. Methods to simulate allergy and measure efficacy of drugs are the conjunctival allergen challenge and the conjunctival provocation test. Pharmacologic outcome is measured via cytologic biomarkers and clinical signs/symptoms of redness, itching, lid swelling and chemosis. Endpoint instruments such as the Ocular Allergy Index and Eye Allergy Patient Impact Questionnaire have emerged from the field of pharmacoeconomics. SUMMARY: Important pharmacologic properties of targets have been revealed. First, histamine is more specifically antagonized by second generation antihistamines. Second, newly formed mediators and downstream responders (prostaglandins, leukotrienes, interleukins, intercellular adhesion molecule 1, tumor necrosis factor, vascular cell adhesion molecule, eosinophils and neutrophils) are more selectively antagonized by dual/multiple-action agents.

Conjunctivitis, Allergic↗